OPB-111077
- Generic Name
- OPB-111077
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation. It has demonstrated promising anticancer activity in preclinical models.
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-08-08
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04049825
- Locations
- 🇯🇵
Yamagata University Hospital, Yamagata, Japan
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2021-02-15
- Lead Sponsor
- Hospital Universitario 12 de Octubre
- Target Recruit Count
- 9
- Registration Number
- NCT03197714
- Locations
- 🇪🇸
MD Anderson Cancer Center, Madrid, Spain
🇪🇸Hospital San Pedro Alcántara, Cáceres, Extremadura, Spain
🇪🇸Hospital Universitario Madrid Sanchinarro, Madrid, Spain
Phase IIa Dose-Expansion and Biomarker Study of OPB-111077
- First Posted Date
- 2017-05-18
- Last Posted Date
- 2017-06-15
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 52
- Registration Number
- NCT03158324
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore, Singapore
Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor
- First Posted Date
- 2014-09-26
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT02250170
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seoul, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT01942083
A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer
- First Posted Date
- 2012-10-22
- Last Posted Date
- 2016-04-05
- Target Recruit Count
- 145
- Registration Number
- NCT01711034
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath